New Therapeutic Options for C3G and IC-MPGN

Joel Topf, MD, of Nephrology Times is joined by Cybele Ghossein, MD, Northwestern Medicine; Suneel Udani, MD, Nephrology Associates of Northern Illinois and Indiana; Anthony Chang, MD, University of Chicago; Fernando Fervenza, MD, PhD, Mayo Clinic; and Roger Rodby, MD, Rush University Medical Center, for a roundtable discussion on innovations, insights, and implementation of new treatments for rare kidney disease, in particular, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). In the second segment, the panel discusses two recently approved treatments, iptacopan for C3G and pegcetacoplan for C3G and IC-MPGN.